Juvenile Idiopathic Arthritis

In this edition, guselkumab brings ‘stringent’ control through 2 years, SARDs outpatient visits result in opioid prescriptions and more.

ORLANDO, Fla. — Allowing children with rheumatic diseases the time and space to formulate their own thoughts on their condition can facilitate communication and help them live a normal life, according to a presenter.

Tofacitinib’s benefits in patients with juvenile idiopathic arthritis extend through at least 48 months, with no new safety findings, according to data published in Annals of the Rheumatic Diseases.

Juvenile arthritis can impact the physical and emotional wellbeing of children in unique ways, manifesting in loneliness and depression, according to the Arthritis Foundation.

A systemic review and meta-analysis revealed that higher initial glucocorticoid doses improved lupus nephritis treatment response but increased risks for serious infections and mortality.

Converting an empty building into an information hub and social media campaigns were among the “innovative” strategies employed by a U.K.-based patient organization to raise awareness of juvenile arthritis, according to EULAR.

The FDA has approved the interleukin-6 inhibitor Kevzara for the treatment of polyarticular juvenile idiopathic arthritis, according to a press release from Regeneron Pharmaceuticals and Sanofi.

Male sex, Black race and insurance coverage with Medicaid were among factors associated with increased risk for developing 20/200 or worse vision among children with juvenile idiopathic arthritis-associated uveitis, according to research.

Patients with immune-mediated diseases have higher rates of adverse pregnancy outcomes such as preeclampsia and pre-term delivery, with lupus and systemic sclerosis conferring the largest risks, according to data published in Rheumatology.

Nearly 40% of children with oligoarticular juvenile idiopathic arthritis treated with intra-articular corticosteroids required no additional therapy, according to data published in Arthritis Research & Therapy.